Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related
- 1 May 2005
- journal article
- other
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 91 (1) , 81-87
Abstract
In oestrogen receptor-positive (ER+) breast cancer, HER-2/neu and the progesterone receptor (PR) are inversely associated. This explains a lower response to anti-oestrogens if ER+ breast cancers are HER-2/neu positive. One randomized study however, showed that premenopausal women with an ER+ breast cancer respond to anti-oestrogens independent of HER-2/neu. We therefore hypothesized an age-related association between HER-2/neu and PR in ER+ breast cancers. Receptors for ER, PR and HER-2/neu were analysed by immunohistochemistry (IHC). A uni- and multivariate analyses was carried out to assess this relationship in 1104 women with an ER+ breast cancer. We observed an inverse association between HER-2/neu and PR only after age 45. There were 173 women of age ≤45 and 931 of age >45 years. In multivariate analysis, only tumour grade (p=0.005) but not PR status was associated with HER-2/neu in women age ≤45 years. However, in age >45 years group, both PR status (p=0.001) and tumour grade (p = 0.001) were independently associated with HER-2/neu. In ER+ breast cancers from women age >45, PR was positive in 76.9% if HER-2/neu negative but in 53.4% if HER-2/neu positive (p45 years but not in women age ≤45 years.Keywords
This publication has 21 references indexed in Scilit:
- Do we need HER‐2/neu testing for all patients with primary breast carcinoma?Cancer, 2003
- Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer PatientsBreast Cancer Research and Treatment, 2003
- Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer DatabasesJournal of Clinical Oncology, 2003
- HER-2/neu Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast CancerJournal of Clinical Oncology, 2003
- Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast CancerJNCI: Journal of the National Cancer Institute, 2003
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001
- When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast CancerJournal of Clinical Oncology, 2001
- Prognostic Factors in Breast CancerArchives of Pathology & Laboratory Medicine, 2000
- Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levelsBreast Cancer Research and Treatment, 2000
- Predicting Response to Endocrine Therapy in Human Breast Cancer: A HypothesisScience, 1975